Transthera’s CNS-penetrating NLRP3 inflammasome inhibitor enters IND-enabling studies

Feb. 27, 2024

Transthera Sciences (Nanjing) Inc. has announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLRP3 inflammasome inhibitor.

BioWorld Science Cardiovascular Endocrine/metabolic Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for May 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 14, 2025.

FDA shift from animal testing fuels organoid, organ-on-chip demand

BioWorld Science

The U.S. FDA’s decision to phase out animal testing for INDs is driving a new market of alternative, nonanimal testing technologies like organoids and...

AI generated, 3D rendering of protein degradation

AACR 2025: Induced proximity strategy, beyond degraders

BioWorld

Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...

Three med-tech IPOs on the horizon

BioWorld MedTech

April may not have brought rain to med-tech, but tariffs and financial uncertainty certainly dampened the enthusiasm for IPOs. With those clouds lifting, three...